Document is current
Any future updates will be listed below
-
Authors
DePietro, Michael https://orcid.org/0000-0002-8729-2530
Santos, Leandro L. https://orcid.org/0000-0001-9986-6047
Xue, Zhenyi https://orcid.org/0009-0006-8196-2181
Brown, Kurt https://orcid.org/0009-0004-8876-9777
Brant, Jason A. https://orcid.org/0000-0002-3492-0679
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04818346 at ClinicalTrials.govDocuments that mention this clinical trial
Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients in a Phase 2 Clinical Trial of Povorcitinib
https://doi.org/10.1007/s13555-026-01789-9
Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial
https://doi.org/10.1007/s12325-026-03673-6
-
Funding
Funding for this research was provided by:
Incyte Corporation
- License Information
-
More Information
Article History
Received: 23 January 2026
Accepted: 8 May 2026
First Online: 8 August 2026
Declarations
Conflict of Interest: Michael DePietro, Leandro L. Santos, Zhenyi Xue, and Kurt Brown are employees and shareholders of Incyte. Jason A. Brant reports consultancy fees from Incyte.
Ethical Approval: The study protocol was approved by the institutional review board or ethics committee at each participating site, including WCG (no. 20210846; Cary, NC, USA), the Research Review Board (no. 2021.562; Waterloo, ON, Canada), and the Biomedical Research Ethics Board, University of Manitoba (no. HS24854 [B2021:036]; Winnipeg, MB, Canada). The study was conducted in compliance with the Declaration of Helsinki, study protocol, applicable Good Clinical Practice, and all applicable laws and regulations. All patients provided written informed consent prior to any study procedures being undertaken.
